Researchers at the University of Calgary, Canada, have developed a new vaccine targeting hemorrhagic septicemia, a deadly ...

Scott Gray-Owen, Ph.D., and Dr. Trevor Moraes, Ph.D., developing vaccines for humans and food production animals. Their combined expertise in antigen selection, design and testing provided a ...

Selection of 19 individual researchers among ... Cheever and colleagues establish a definition of 'ideal' antitumor vaccine antigens based on weighted criteria, including: evidence of antitumor ...

Several observations point toward the possibility of a vaccine development strategy ... of most of these surface proteins has made antigen selection problematic. Obstacles to the development ...

This 19th-Century killer is making a comeback – and with protection from the whooping cough vaccine waning over time, the ...

With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones ...

Nov. 18, 2024 — A new nasal whooping cough vaccine showed an ability to prevent both infection and transmission of the disease in mice. Current vaccines offer treatment but fail to halt ...

RNA vaccines are composed of the nucleic acid RNA, which encode antigen genes of an infectious agent. When administered to host cells, the RNA is translated into protein antigens that elicit ...

AI-Immunology™ can select ERV antigens for precision therapeutic cancer vaccines, offering therapeutic options for multiple specific cancer types and potentially enabling treatment for patients ...

The studies investigated human T-cell responses and mouse tumor growth inhibition induced by precision ERV vaccine targets identified using Evaxion’s AI-Immunology™ platform.